Today Deepcell announced the close of a $73 million B round. Their total funding to date is $100 million. The company plans to use this funding to advance its AI powered single cell analysis platform. Investors in this round included Koch Disruptive Technologies, Andreessen Horowitz, Horizons Ventures, Bridger Healthcare, Casdin Capital and Bow Capital. Jeff Dean, Head of Google Brain, and Matt Mcllwain, Managing Director at Madrona Venture Group also participated in this round. Past investors in the company’s seed round and series A include Fifty Years, Data Collective, and Stanford University.
Deepcell combines state-of-the-art machine learning, microfluidics, imaging, and genomics to power phenotype activated cell analysis and sorting. Since Deepcell’s AI-powered technology can isolate and capture any cell population based on morphological features, it can be used for a wide variety of research, translational applications, diagnostic testing, and therapeutics. The technology allows for the delivery of intact and viable single cells at high precision with no bias and can be used to isolate any type of cell, even those occurring at frequencies as low as one in a billion. This enables researchers to characterize and gain new insights from single cells at levels of resolution previously unseen with other omics based tools.